DeCure for Autoimmune lymphoproliferative syndrome type 2B
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for autoimmune lymphoproliferative syndrome type 2B — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutoimmune lymphoproliferative syndrome type 2B maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autoimmune lymphoproliferative syndrome type 2b is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
caspase 8 (CASP8) — CASP8 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8YNM · 3.49 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Autoimmune lymphoproliferative syndrome type 2B is not directly named in any of the three abstracts. The 2001 review describes ALPS type II as caused by a mutation of the Caspase-10 gene, and notes that a further subgroup, ALPS type III, has no identified genetic defect. The review states that ALPS type III is difficult to diagnose because of variable clinical presentation and the absence of a known mutation, and suggests it may be more common than previously believed. No treatment data, survival figures, or response rates for any ALPS subtype are given in that paper.
The 2018 case report concerns methotrexate-associated lymphoproliferative disorders in patients on immunosuppressants for long-standing autoimmune diseases, not ALPS. Sustained regression of those lymphoproliferative disorders occurred after discontinuation of the immunosuppressive agents. The 2010 paper states that no case of ALPS had been reported in China at that time, and describes the syndrome as a rare group of disorders with complex pathogenesis and clinical features that are easily missed.
No abstract provides any clinical trial, drug treatment, or outcome data for autoimmune lymphoproliferative syndrome type 2B. What is missing is any prospective trial, any biomarker for patient stratification, and any funding for a disease that remains diagnostically elusive and for which no specific therapy is tested in the available literature.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Leukemia & lymphoma/Leukemia and lymphoma · 2001 · 30 citations
Autoimmune Lymphoproliferative Syndrome Type III: An Indefinite Disorder
AbstractAutoimmune Lymphoproliferative Syndrome (ALPS) is a childhood disorder characterized by chronic nonmalignant lymphoproliferation and autoimmunity. Although the pathogenesis is not fully understood, deficient Fas mediated apoptosis appears to be an important factor. This deficiency can be caused by a mutation of the APT1 gene (ALPS type Ia), of the FasL gene (ALPS type Ib), or of the Caspase-10 gene (ALPS type II). In one sub population of patients, no mutations have been identified as yet (ALPS type III). According to published data, the latter group is much smaller than the group of patients with ALPS type Ia. However, because of the variability of the clinical presentation and the absence of a known genetic defect, this disease is difficult to diagnose, the more so as few data have been reported on these patients. Thus, ALPS type III could be more common than believed until now. In this review we provide evidence for this hypothesis.
Pediatrics International · 2018 · 7 citations · open access
Low‐dose sirolimus in two cousins with autoimmune lymphoproliferative syndrome‐associated infection
AbstractAutoimmune lymphoproliferative syndrome (ALPS) is characterized by non-malignant lymphoproliferation and autoimmunity, with a wide spectrum of clinical manifestations (OMIM 601859). Typical features include enlarged spleen and lymph nodes and autoimmune cytopenia. We describe a family with ALPS in which two cousins independently presented to their physicians with infection and discuss the therapeutic potential of sirolimus.
BMJ Case Reports · 2018 · 2 citations · open access
Treatment of advanced stage methotrexate-associated lymphoproliferative disorders (MTX-LPDs) with methotrexate discontinuation
AbstractWe present two cases of patient's with long-standing autoimmune diseases being treated with immunosuppressants that developed aggressive lymphoproliferative disorders. Immunosuppressants have a well-known association with disorders. Sustained regression of these lymphoproliferative disorders occurred with simple discontinuation of these immunosuppressive agents.
International journal of pediatrics · 2010 · 0 citations
Progress of autoimmune lymphoproliferactive syndrome
AbstractAutoimmune lymphoproliferactive syndrome is a rare group disorders associated with self stability and immune tolerance of lymphocyte due to genetic mutation which affects the lymphocyte apoptosis .The clinical manifestations comprise lymphoproliferation, development of autoimmunity and malignancies.The pathogenesis and clinical features are complex ALPS were easily missed and no case had been reported until now in China.
Key words:
Autoimmunity; Apoptosis; FAS gene; Double negative T cell
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
